Constipation News and Research RSS Feed - Constipation News and Research

Constipation is a condition in which stool becomes hard, dry, and difficult to pass, and bowel movements don’t happen very often. Other symptoms may include painful bowel movements, and feeling bloated, uncomfortable, and sluggish.
New pain management strategies key to maximizing patient outcomes after TKR procedures

New pain management strategies key to maximizing patient outcomes after TKR procedures

According to a new literature review in the February issue of the Journal of the American Academy of Orthopaedic Surgeons, a team-based care approach (consisting of the patient, family members, the orthopaedic surgeon and other medical practitioners) on total knee replacement (TKR) procedures, in conjunction with newer pain management strategies, is key to maximizing patient outcomes. [More]
Eisai's Halaven receives FDA approval for treatment of patients with metastatic liposarcoma

Eisai's Halaven receives FDA approval for treatment of patients with metastatic liposarcoma

Eisai Inc. announced today that the U.S. Food and Drug Administration approved Halaven (eribulin mesylate) Injection (0.5 mg per mL) for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. [More]
AbbVie announces initiation of first Elagolix Phase 3 study in patients with uterine fibroid

AbbVie announces initiation of first Elagolix Phase 3 study in patients with uterine fibroid

AbbVie, in cooperation with Neurocrine Biosciences, Inc., today announced the initiation of the first of two planned Phase 3 clinical studies evaluating the safety and efficacy of Elagolix alone or in combination with add-back therapy compared to placebo. [More]
Halaven (eribulin mesylate) approved for treatment of liposarcoma

Halaven (eribulin mesylate) approved for treatment of liposarcoma

The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate), a type of chemotherapy, for the treatment of liposarcoma (a specific type of soft tissue sarcoma) that cannot be removed by surgery (unresectable) or is advanced (metastatic). This treatment is approved for patients who received prior chemotherapy that contained an anthracycline drug. [More]
Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

Astellas US LLC, a United States (U.S.) subsidiary of Tokyo-based Astellas Pharma Inc., and Medivation, Inc. today announced that results from the STRIVE trial of enzalutamide compared to bicalutamide in men with castration-resistant prostate cancer (CRPC) were published in the Journal of Clinical Oncology. [More]
Allergan announces publication of VIBERZI Phase III trial results in The New England Journal of Medicine

Allergan announces publication of VIBERZI Phase III trial results in The New England Journal of Medicine

Allergan plc announced today the publication of the positive results of the Phase III trials of VIBERZITM C IV (eluxadoline) for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in the January 21 issue of The New England Journal of Medicine. [More]
Researchers reveal biological connection between obesity and colorectal cancer risk

Researchers reveal biological connection between obesity and colorectal cancer risk

Obesity has long been associated with increased risk of colorectal cancer, but the link has never been understood. Now, a research team led by investigators at Thomas Jefferson University has revealed the biological connection, and in the process, has identified an approved drug that might prevent development of the cancer. [More]
U.S. Marshals seize nearly 90,000 bottles of dietary supplements containing kratom

U.S. Marshals seize nearly 90,000 bottles of dietary supplements containing kratom

The U.S. Food and Drug Administration announced today that U.S. Marshals, at the agency's request, seized nearly 90,000 bottles of dietary supplements labeled as containing kratom. The product, manufactured for and held by Dordoniz Natural Products LLC, located in South Beloit, Illinois, is marketed under the brand name RelaKzpro and worth more than $400,000. [More]
Ardelyx announces positive results from RDX022 clinical study for treatment of hyperkalemia

Ardelyx announces positive results from RDX022 clinical study for treatment of hyperkalemia

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced positive results of an open label clinical study evaluating the pharmacodynamic (PD) activity of RDX022 in healthy adult volunteers. [More]
FDA issues two final orders to strengthen requirements for transvaginal surgical mesh safety

FDA issues two final orders to strengthen requirements for transvaginal surgical mesh safety

The U.S. Food and Drug Administration today issued two final orders to manufacturers and the public to strengthen the data requirements for surgical mesh to repair pelvic organ prolapse (POP) transvaginally, or through the vagina. [More]
New oral breast cancer drug has potential to combat other types of cancer

New oral breast cancer drug has potential to combat other types of cancer

Palbociclib, a new oral drug whose efficacy in combating breast cancer has been demonstrated alone and in combination with endocrine therapy, also has potential to combat other types of cancer, according to a literature review and additional original research conducted by experts at the Abramson Cancer Center in the University of Pennsylvania published this month in JAMA Oncology. [More]
Study looks at long-term effects of psychological therapies in patients with irritable bowel syndrome

Study looks at long-term effects of psychological therapies in patients with irritable bowel syndrome

For some time doctors have known that psychological therapies can reduce the symptoms of irritable bowel syndrome in the short term. [More]
Vitamin D plays substantial role in patient outcomes after weight-loss surgery

Vitamin D plays substantial role in patient outcomes after weight-loss surgery

Low levels of vitamin D have long been identified as an unwanted hallmark of weight loss surgery, but now findings of a new Johns Hopkins study of more than 930,000 patient records add to evidence that seasonal sun exposure -- a key factor in the body's natural ability to make the "sunshine vitamin" -- plays a substantial role in how well people do after such operations. [More]
Alecensa (alectinib) approved for treatment of people with advanced ALK-positive NSCLC

Alecensa (alectinib) approved for treatment of people with advanced ALK-positive NSCLC

The U.S. Food and Drug Administration today approved Alecensa (alectinib) to treat people with advanced (metastatic) ALK-positive non-small cell lung cancer (NSCLC) whose disease has worsened after, or who could not tolerate treatment with, another therapy called Xalkori (crizotinib). [More]
Lilly, Merck announce another immuno-oncology collaboration

Lilly, Merck announce another immuno-oncology collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck's KEYTRUDA (pembrolizumab) in a Phase I study across multiple tumor types. [More]
Cognitive behavioral therapy can be equally effective as second generation antidepressant for depression

Cognitive behavioral therapy can be equally effective as second generation antidepressant for depression

Major depressive disorder affects more than 32 million Americans, and their first stop for treatment is often their primary care provider. A recent evidence review of several alternatives to medication found that using cognitive behavioral therapy as the first treatment for depression can be equally effective as using a second generation antidepressant. [More]
Kanuma approved as first treatment for patients with LAL deficiency

Kanuma approved as first treatment for patients with LAL deficiency

Today, the U.S. Food and Drug Administration approved Kanuma (sebelipase alfa) as the first treatment for patients with a rare disease known as lysosomal acid lipase (LAL) deficiency. [More]
Takeda presents Phase 3 TOURMALINE-MM1 data for multiple myeloma at ASH 2015

Takeda presents Phase 3 TOURMALINE-MM1 data for multiple myeloma at ASH 2015

Takeda Pharmaceutical Company Limited today announced results from the TOURMALINE-MM1 trial presented at the 57th Annual Meeting and Exposition of the American Society of Hematology (ASH), showing that treatment with NINLARO (ixazomib) capsules is effective in extending progression free survival (PFS) with a manageable tolerability profile in patients with relapsed and/or refractory multiple myeloma. [More]
Synthetic Biologics announces positive results from first SYN-004 Phase 2a study for prevention of CDI, AAD

Synthetic Biologics announces positive results from first SYN-004 Phase 2a study for prevention of CDI, AAD

Synthetic Biologics, Inc.), a clinical stage company focused on developing therapeutics to protect the gut microbiome while targeting pathogen specific diseases, announced positive topline results from the first Phase 2a study of SYN-004, the Company's candidate designed to protect the gut microbiome from the unintended effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention C. difficile infection (CDI) and antibiotic-associated diarrhea (AAD). [More]
FDA grants approval for Empliciti (elotuzumab) to treat patients with multiple myeloma

FDA grants approval for Empliciti (elotuzumab) to treat patients with multiple myeloma

Today the U.S. Food and Drug Administration granted approval for Empliciti (elotuzumab) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications. [More]
Advertisement
Advertisement